Helixmith
Helixmith Co., Ltd is an R&D-focused biopharmaceutical company based in Seoul and San Diego, developing new and innovative biopharmaceuticals based upon its proprietary scientific platform technology to address unmet medical needs. Currently, the company is actively focusing on developing the proprietary plasmid DNA-based drug Engensis at various clinical stages in the U.S., Korea, and China for cardiovascular and neurological diseases including, but not limited to, painful DPN, diabetic foot ulcer (DFU), amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease (IHD). The company also has early phase pipeline in AAV-based gene therapy and CAR-T cell therapy.
